Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing next-generation precision medicines targeting FGFR biology. The news flow around TYRA, as reflected in its recent press releases, centers on clinical trial progress, scientific presentations, regulatory designations and corporate developments related to its FGFR-focused pipeline.
Investors and followers of TYRA news can expect updates on dabogratinib (formerly TYRA-300), the company’s lead oral FGFR3-selective inhibitor. Recent announcements include dosing the first patient in the SURF302 Phase 2 study for FGFR3-altered intermediate risk non-muscle invasive bladder cancer, dosing the first child in the BEACH301 Phase 2 study for pediatric achondroplasia, and plans to expand development into low-grade upper tract urothelial carcinoma through the SURF303 study. Tyra also reports interim proof-of-concept results in metastatic urothelial carcinoma and regulatory designations such as Orphan Drug Designation and Rare Pediatric Disease Designation for dabogratinib in achondroplasia.
News coverage further highlights progress in early-stage oncology programs TYRA-200 and TYRA-430, including enrollment and dosing in the SURF201 and SURF431 Phase 1 studies for intrahepatic cholangiocarcinoma, hepatocellular carcinoma and other FGFR-driven tumors. Tyra’s communications also describe scientific visibility events, such as a late-breaking poster on TYRA-300 preclinical data at ENDO 2025 and fireside chats or presentations at healthcare and biotechnology investor conferences.
In addition, Tyra Biosciences issues quarterly financial results press releases and Form 8-K filings that summarize research and development spending, cash runway expectations and key clinical milestones. Corporate news has included strengthening the leadership team with appointments in operations and regulatory affairs. For readers tracking TYRA, this news stream provides ongoing insight into the company’s clinical development timelines, scientific activities and corporate priorities in FGFR-targeted precision medicine.
Tyra Biosciences (Nasdaq: TYRA) announced its participation in key investor conferences on November 14 and 15-17, 2022. CEO Todd Harris will engage in fireside chats at both events, aiming to showcase the company's innovations in precision oncology. The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference will feature a chat available on demand, while the Jefferies London Healthcare Conference will include a live chat on November 15 at 10:50 am ET. Webcasts of these discussions will be accessible on the TYRA Investor section.
Tyra Biosciences, Inc. (TYRA) reported its third-quarter 2022 financial results, highlighting a net loss of $12.5 million, an increase from $6.6 million in Q3 2021. Research and development expenses rose to $10.9 million, compared to $5.5 million in the prior year. As of September 30, 2022, cash and cash equivalents stood at $263.2 million. The company is focused on advancing its pipeline, which includes the initiation of the SURF301 study for TYRA-300 and filing an IND for TYRA-200 by year-end 2022.
Tyra Biosciences (Nasdaq: TYRA) announced a leadership transition, with Esther van den Boom stepping down as Chief Financial Officer to become an advisor at the end of 2022. Alan Fuhrman will assume the CFO role on January 1, 2023. CEO Todd Harris praised van den Boom's contributions and expressed confidence in Fuhrman's experience guiding companies through growth phases, including clinical development. Fuhrman looks forward to advancing TYRA's precision oncology pipeline, particularly the FGFR-targeting therapies, including TYRA-300, which has received FDA IND clearance.
Tyra Biosciences (Nasdaq: TYRA) will present preclinical data on its FGFR1/2/3 inhibitor, TYRA-200, at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 26-28, 2022. The presentation is scheduled for October 26 and focuses on TYRA-200's effectiveness against FGFR2 fusions, molecular brake mutations, and gatekeeper resistance, with the aim of enhancing outcomes for cancer patients. This event is pivotal as the company seeks to advance its pipeline targeting critical genetic alterations affecting cancer treatment.
Tyra Biosciences (Nasdaq: TYRA), a precision oncology firm, announced its participation in key investor conferences. Management will present a pre-recorded session at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, with the presentation available on September 12 at 7 AM ET. Additionally, Tyra will be featured at the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, with a panel discussion at 11:30 AM ET. Tyra is focused on therapies to overcome tumor resistance and is developing selective FGFR inhibitors.
Tyra Biosciences, Inc. (Nasdaq: TYRA) announced the presentation of preclinical data on TYRA-300, an FGFR3-selective inhibitor, at the ESMO 2022 Congress in Paris from September 9-13, 2022. CEO Todd Harris highlighted the promising anti-tumor activity of TYRA-300 compared to other agents. This data supports the upcoming SURF301 Phase 1/2 clinical study, which the FDA has already authorized. The poster presentation will occur on September 12, 2022, showcasing the drug's potential in treating metastatic urothelial carcinoma.
Tyra Biosciences announced the FDA's IND clearance for its SURF301 study of TYRA-300, an FGFR3-selective inhibitor for bladder cancer. The company is on track to file an IND for TYRA-200 in the second half of 2022 and reported a strong cash position of $275.1 million as of June 30, 2022. Despite progress, the net loss for Q2 2022 was $15.1 million, up from $5.5 million in Q2 2021, with increased R&D expenses of $12.0 million compared to $4.4 million from the prior year.
Tyra Biosciences (TYRA) reported its Q1 2022 financial results, highlighting a net loss of $14.8 million, up from $4.2 million in Q1 2021. Operating expenses rose significantly with research and development costs reaching $9.6 million and general administrative expenses at $5.2 million. The company has cash and equivalents of $292.5 million as of March 31, 2022, reassuring investors of its financial stability. Tyra plans to file INDs for its lead product candidates, TYRA-300 and TYRA-200, by mid-2022 and the second half of 2022, respectively.
Tyra Biosciences (Nasdaq: TYRA) reported its fourth quarter and full year 2021 financial results, highlighting a net loss of $9.9 million for Q4 and $26.3 million for the year, compared to $3.7 million and $9.3 million, respectively, in 2020. R&D expenses surged to $7.2 million in Q4 from $2.9 million a year prior, while total cash reached $302.2 million. Anticipated FDA IND submissions for TYRA-300 and TYRA-200 are planned for 2022, alongside a strengthening of the clinical team.
Tyra Biosciences (Nasdaq: TYRA) announced its participation in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022. CEO Todd Harris will be featured in a panel on March 8, 2022, at 9:10 am ET. The event aims to highlight the company's focus on precision oncology and its proprietary SNÅP platform to develop therapies targeting tumor resistance. Investors can access a live webcast on the company's website. Tyra specializes in inhibitors for the Fibroblast Growth Factor Receptor (FGFR) family, crucial in treating various cancers.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
